Larisa V. Filatova

Larisa V. Filatova

Auto-generated profile, based on publicly available information

Larisa V. Filatova

NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
NBNadezhda A. Brish
Nadezhda A. Brish
TSTatiana Yu. Semiglazova
Tatiana Yu. Semiglazova
AKAleksei M. Karachun
Aleksei M. Karachun
LSLev N. Shevkunov
Lev N. Shevkunov
YUYana A. Ulyanchenko
Yana A. Ulyanchenko
БМБеляев Алексей Михайлович
Беляев Алексей Михайлович
Aim. To increase the effectiveness of neoadjuvant chemotherapy in patients with locally advanced gastric cancer by correcting nutritional deficiency. Materials and methods. Of 200 patients with locally advanced gastric cancer (mean age 57.2 years (46.168.3), 100 patients received neoadjuvant chemotherapy with nutritional support from 2018 to 2020. One hundred patients received neoadjuvant chemotherapy without nutritional support from 2013 to 2018 (historical control). The incidence of nutritional deficiency before treatment in the neoadjuvant chemotherapy + nutritional support group was 54%, and in the neoadjuvant chemotherapy only group it was 47%. Nutritional status was assessed using anthropometry, questionnaires (NRS-2002, MUST, GLIM), dynamometry, blood tests, bioimpedance. Complications according to NCI CTCAE v5.0; оbjective response rate according to RECIST 1.1; pathomorphological regression according to the JGCA classification (2017); 2-year event-free survival were assessed. Results. The frequency of nutritional deficiency before the start of treatment in the neoadjuvant chemotherapy + nutritional support group was 54%, in the neoadjuvant chemotherapy only group 47%. After the completion of neoadjuvant chemotherapy in the group neoadjuvant chemotherapy + nutritional support the frequency of nutritional deficiency was 1%, in the group neoadjuvant chemotherapy only without nutritional support 62%. In patients with nutritional deficiency in the neoadjuvant chemotherapy + nutritional support group, partial regression was registered in 51.9% of cases, in the neoadjuvant chemotherapy only group it was 27.6% (p0.05). There were no differences in the frequency of pathological response. 2-year event-free survival in patients without nutritional deficiency in the group neoadjuvant chemotherapy + nutritional support was 100%, in the neoadjuvant chemotherapy only group it was 68.5% (p0.001); in patients with nutritional deficiency 72,5 and 60.6% respectively (p0.05). Conclusion. Nutritional deficiency is an important predictive and prognostic marker of the efficacy of neoadjuvant chemotherapy in the treatment of locally advanced gastric cancer. Comprehensive diagnosis of nutritional status and nutritional support can improve the results of neoadjuvant chemotherapy in patients with locally advanced gastric cancer.

28 February 2023 in Cancer Reports
Verified
Journal Article
Open access
AKAleksei K. Koviazin
Aleksei K. Koviazin
LFLarisa V. Filatova
Larisa V. Filatova
IZIlia S. Zyuzgin
Ilia S. Zyuzgin
AAAnna S. Artemyeva
Anna S. Artemyeva
IPIlia L. Poliatskin
Ilia L. Poliatskin
TSTatiana Yu. Semiglazova
Tatiana Yu. Semiglazova
Background: Diffuse large B‐cell lymphoma (DLBCL) is the most common (30%–35%) type of B‐cell lymphoma. Only about 60% of all newly diagnosed advanced‐stage DLBCL can be completely treated with x6 R‐CHOP. High‐dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation in the first remission (upfront auto‐HSCT) can serve as an option to improve a prognosis in these patients.Aims: This trial aimed to improve prognosis in DLBCL by upfront auto‐HSCT.Methods and Results: A group of 105 patients: DLBCL NOS, age 18–65, stage IV, IPI ≥2, CR/PR after x6 R‐CHOP/DA‐EPOCH‐R from 2010 to 2019 at NMRC of Oncology named after N.N.Petrov of MoH of Russia was retrospectively analyzed. The HSCT group included patients with upfront HDCT followed by auto‐HSCT (n = 35). The control group included patients with non‐invasive follow‐up after induction (n = 70). Primary endpoint was progression‐free survival (PFS). Secondary endpoints were overall survival (OS), response rate and relapse rate. The 3‐year OS (p = .013) and 3‐year PFS (p = .033) were significantly higher in the HSCT group. The 3‐year OS was decreased by the occurrence of relapse (p ≤ .001) and weight loss (B‐symptom) (p = .04). DEL was the negative prognostic factor for 3‐year PFS in all patients (p = .001) and control group (p = .001). DA‐EPOCH‐R significantly increased the 3‐year PFS (p = .041).Conclusion: Upfront HDCT followed by auto‐HSCT can increase 3‐year OS and PFS and improve prognosis in DLBCL NOS, age 18–65, stage IV, IPI ≥2 patients.

8 December 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
KKK. E. Katsuba
K. E. Katsuba
LKL. A. Kramynin
L. A. Kramynin
MSMaria Slyusarenko
Maria Slyusarenko
ASAndrey Vladimirovich Shalaev
Andrey Vladimirovich Shalaev
Vladimir SharoykoVladimir Sharoyko
Vladimir Sharoyko
Anastasia MalekAnastasia Malek
Anastasia Malek
Background. In current clinical practice, there are no reliable methods to stratify patients with a high risk of relapse or with a primary refractory form of Hodgkin lymphoma. Quantification of CD30-positive small extracellular vesicles (CD30(+)SEV) in plasma seems to be a possible approach to solve this issue. CD30(+)SEV can be quantified by the AuNP aptasensor technology based on the enzyme-mimetic properties of gold nanoparticles and the CD30-specific affinity of DNA aptamers.Aim. To quantify CD30(+)SEV in the plasma of patients with newly diagnosed Hodgkin lymphoma; to investigate the links between estimated parameter and clinical/morphological properties of disease and the effect of first two chemotherapy cycles.Material and methods. A semi-quantitative analysis of CD30(+)SEV in the plasma of patients with Hodgkin lymphoma (n = 55) was performed using the AuNP aptasensor. The relationship between the CD30(+)SEV concentration and the data of standard diagnostic approaches was evaluated through the r-Pearson correlation coefficient, the Mann–Whitney and Kruskal–Wallis criteria.Results. The plasma concentration of CD30(+)SEV in patients with Hodgkin lymphoma correlates with the quantity of CD30(+) cells in tissues of biopsied lymph nodes (r = 0.8) and the total lesion glycolysis estimated by PET/CT (r = 0.9). Patients with a relatively high concentration of CD30(+)SEV are characterized by an increase of erythrocyte sedimentation rate and leukocytosis compared with patients with a lower concentration of CD30(+)SEV. Two cycles of chemotherapy reduced CD30(+)SEV concentration, and this effect was more pronounced in patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regime than the BEACOPPesc (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, procarbazine).Conclusion. AuNP-aptasensor can be used for semi-quantitative assessment of CD30(+)SEV in plasma. The estimated CD30(+)SEV concentration correlates with the clinical and morphological parameters of patients with Hodgkin lymphoma and may reflect the severity of the disease. To assess the diagnostic and/or prognostic potential of developed technology, large-scale multicenter studies are required.

16 June 2024 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
SASh.R. Abdullaeva
Sh.R. Abdullaeva
TST.YU. Semiglazova
T.YU. Semiglazova
AAA.S. Artemyeva
A.S. Artemyeva
VZV.A. Zagoruiko
V.A. Zagoruiko
TKT.I. Kudriashova
T.I. Kudriashova
VSV.F. Semiglazov
V.F. Semiglazov
BACKGROUND Tumor infiltrating lymphocytes (TILs) are a promising inexpensive prognostic and predictive biomarker in breast cancer. High levels of TILs are associated with improved survival and higher probability to achieve pathological complete response in triple-negative breast cancer (TNBC). OBJECTIVE To assess the level of TILs in TNBC samples and analyze the association between the level of TILs and the main pathological parameters, to identify their impact on long-term results. MATERIAL AND METHODS The study included information on 140 patients with I-III stage TNBC and estrogen receptors <10%. Tumor tissue samples at baseline biopsies were evaluated the histological type, HER2 expression, estrogen expression levels, Ki-67 and TILs. The pathological response was evaluated according to the ypTNM, Miller—Payne, and RCB classifications. RESULTS The average level of TILs in biopsy specimens before NACT was 29.3±23.1%. Low levels of TILs (40%) in 24% of cases. Using the two-tiered system, low TILs (≤40%) were defined in 76% and high TILs (>40%) in 24% of cases. The level of TILs was correlated with histological grade (R=0.187; p=0.027) and estrogen receptor expression level (R=0.211; p=0.012). There were no significant differences depending on the level of TILs and other pathological parameters. Three-year event-free survival (EFS) in patients with high TILs levels was 95% versus 65% in the low TILs group (p=0.037). CONCLUSION Stromal TILs are an important prognostic biomarker in TNBC. Using a cutoff of 40%, high TILs are significantly associated with longer EFS.

1 November 2023 in Voprosy onkologii
Verified
Journal Article
Open access
БКБорис Сергеевич Каспаров
Борис Сергеевич Каспаров
ДКДенис Викторович Ковлен
Денис Викторович Ковлен
ТСТатьяна Юрьевна Семиглазова
Татьяна Юрьевна Семиглазова
КККристина Орхановна Кондратьева
Кристина Орхановна Кондратьева
ГПГеннадий Николаевич Пономаренко
Геннадий Николаевич Пономаренко
АБАлексей Михайлович Беляев
Алексей Михайлович Беляев
An increase in the life expectancy of resectable non-small cell lung cancer (NSCLC) patients after complex treatment is associated with psychological and physical impairments that reduce the overall quality of life. The article evaluates the efficacy of rehabilitation programs in NSCLC patients, considering recommended technologies (RT) of physical and rehabilitation medicine (personalized approach) in comparison to standard rehabilitation methods. Materials and methods. The study included 240 patients with resectable NSCLC aged 45 to 71 years (median 60.2 years) who underwent rehabilitation as part of combined/complex treatment at the N.N. Petrov NMRC of Oncology between 2017 and 2022. Patients in the experimental group received personalized rehabilitation, while the control group underwent standard rehabilitation. The control group patients were paired based on key characteristics, including gender, age, functional status, histological subtype, disease stage, and treatment volume. The dynamics of patient parameters were evaluated in the pre-/post-operative period, immediately after implementing the rehabilitation programs, and one year later. The evaluation included an assessment of clinical status indicators (mMRC scale, COMP scale, VAS, 6-minute walk test), functional (PFTs) and psychophysiological parameters (MFI-20 scale, HADS scale), as well as quality of life indicators (EORTC-QLQ30). Results. Analysis of rehabilitation effectiveness in NSCLC patients showed that the personalized rehabilitation model in the experimental group was effective in 86 % of cases, whereas standard rehabilitation programs in the control group were effective in 76 % of cases. The main determinants influencing the therapeutic effect following the application of rehabilitation programs tailored to the selected RTs are: the parameters of external respiration function (VC – vital capacity, PEFR – peak expiratory flow rate, MEF – mean expiratory flow rate), the 6-minute walk test, dyspnea severity scales (Modified Medical Research Council, mMRC), and activities of daily living (Canadian Occupational Performance Measure, COMP). Conclusion. Identified determinants will allow for the early prediction of the effectiveness of rehabilitation technologies in specific models of resectable NSCLC patients, taking into account initial parameters. Увеличение продолжительности жизни больных операбельным немелкоклеточным раком легкого (НМРЛ) после комплексного лечения сопряженно с нарушениями психологического и физического функционирования, снижающими общее качество жизни. В статье приводится оценка эффективности реабилитационных программ у больных операбельным НМРЛ с учётом рекомендованных технологий (РТ) физической и реабилитационной медицины (персонализированный подход) в сравнении со стандартным подходом к реабилитации. Материалы и методы. В исследование были включены 240 пациентов с операбельным НМРЛ в возрасте от 45 до 71 года (медиана 60,2 года), получавших реабилитацию в рамках комбинированного/комплексного лечения в ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России в период с 2017 по 2022 гг. Пациентам в экспериментальной группе применялась персонализированная модель реабилитации. Согласно дизайну исследования в контрольную группу (стандартные реабилитационные мероприятия) были подобраны попарно пациенты, соответствующие больным экспериментальной группы по основным характеристикам: полу, возрасту, функциональному состоянию, гистологическому подтипу, стадии заболевания, объёму лечения. Динамика показателей пациентов была исследована в пред-/послеоперационный период, непосредственно после реализации программ реабилитации и через 1 год, включала оценку показателей клинического статуса (Шкала mMRC, Шкала COMP, ВАШ, 6-минутный тест ходьбы), функциональных (ФВД) и психофизиологических показателей (Шкала MFI-20, Шкала HADS), показателей качества жизни (EORTC-QLQ30). Результаты. Анализ показателей эффективности реабилитации больных НМРЛ показал, что в экспериментальной группе (персонализированная модель реабилитации), реабилитация была эффективна у 86 % пациентов, в то время как в контрольной группе (стандартные программы реабилитации) — в 76 % случаев. Основными детерминантами, влияющими на формирование лечебного эффекта после применения реабилитационных программ, составленных с учётом...

28 February 2025 in Voprosy onkologii
Verified
Journal Article
Open access
ТСТатьяна Юрьевна Семиглазова
Татьяна Юрьевна Семиглазова
ОПОльга Игоревна Понасенко
Ольга Игоревна Понасенко
ВЛВарвара Андреевна Лященко
Варвара Андреевна Лященко
ШАШейда Раджабалиевна Абдуллаева
Шейда Раджабалиевна Абдуллаева
ТКТатьяна Ивановна Кудряшова
Татьяна Ивановна Кудряшова
ВСВладимир Федорович Семиглазов
Владимир Федорович Семиглазов
Достижения последних лет в усовершенствовании методов лечения рака молочной железы (РМЖ) позволили значительно увеличить общую выживаемость среди больных. Наибольшее значение приобретает качество жизни данной категории пациентов в отдаленных перспективах, на которое оказывают влияние поздние осложнения проведенной ранее гормонотерапии и химиотерапии. Так, длительная адъювантная гормонотерапия способствует ускорению темпа потери минеральной плотности костной ткани со скоростью от 2 до 11 % в год, приводя к развитию остеопороза и увеличению риска патологических переломов. Такие широко используемые в лечении РМЖ препараты как антрациклиновые антибиотики и трастузумаб обладают как острой, так и отсроченной кардиотоксичностью, в результате возрастает риск развития поздних сердечно-сосудистых событий через 5 и более лет после завершения лечения. Помимо этого, комплексное лечение РМЖ оказывает отрицательное влияние на фертильность, снижая вероятность наступления беременности на 60 %. Однако имеющиеся данные указывают на отсутствие негативного влияния беременности после завершения комплексного лечения РМЖ на онкологические исходы. В данном обзоре литературы будут рассмотрены имеющиеся данные о механизмах развития, методах профилактики, диагностики и лечения остеопороза и кардиотоксичности, индуцированных химиотерапией и гормонотерапией, а также проблемы фертильности после комплексного лечения РМЖ. Помимо этого, будут затронуты вопросы приверженности лечению (комплаенса) и наблюдения за пациентами после завершения лечения. Подчеркивается, что мультимодальный персонализированный подход с привлечением специалистов различных медицинских направлений позволяет своевременно диагносцировать и эффективно лечить поздние осложнения лекарственной терапии РМЖ, способствовать стойкой ремиссии.